Endometrial Cancer Trial, Recruiting NCT02993900 Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT02993900
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with cancer that has been confirmed through a tissue or cell sample test.
  • You have cancer of the cervix, uterus, vagina, vulva, or urethra at a stage or situation where internal radiation implant treatment is appropriate (confirm with trial site for your specific stage or situation).
  • You are 18 years of age or older.
  • Your doctor expects you to live for more than 6 months.
  • You are generally able to carry out daily activities and care for yourself, as assessed by your doctor.
  • You have had an MRI scan of the pelvis or a PET-CT scan within the past 4 months before joining the trial.
  • You have previously received radiation therapy or chemotherapy (this does not prevent you from joining).
  • You are able to understand the study and are willing to sign a consent form agreeing to take part.

Who may not be able to join:

  • You have a serious uncontrolled illness, such as an active infection, uncontrolled heart failure, unstable chest pain, irregular heartbeat, or a mental health or personal situation that would make it difficult to follow the study requirements.
  • Your white blood cell count (specifically infection-fighting cells called neutrophils) is very low at the time of enrollment.
  • You have a history of metal in your head or eyes.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Akila Viswanathan, M.D., Johns Hopkins Department of Radiation Oncology

Phone: 410-614-1598

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 December 2016
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Dosing changes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov